Reading and Resources

Dietrichs E, et al. Algorithms for the treatment of motor problems in Parkinson’s disease. Acta Neurol Scand. 2017;136:378–385. https://www.ncbi.nlm.nih.gov/pubmed/28133726

Dorsey ER, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68:384-386. https://www.ncbi.nlm.nih.gov/pubmed/17082464

Espay AJ. Management of motor complications in Parkinson disease: current and emerging therapies. Neurol Clin. 2010;28:913-925. https://www.ncbi.nlm.nih.gov/pubmed/17082464

Espay AJ et al. Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy. Neurol Clin Pract. 2017;7:86-93. https://www.ncbi.nlm.nih.gov/pubmed/28243505

Fasano A, et al. Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol. 2015;14:625‐639. https://www.ncbi.nlm.nih.gov/pubmed/25987282

Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015;386:896-912. https://www.ncbi.nlm.nih.gov/pubmed/25904081

Krishnan S, et al. Do nonmotor symptoms in Parkinson’s disease differ from normal aging? Mov Disord. 2011;26:2110-2113. https://www.ncbi.nlm.nih.gov/pubmed/21661056

Marrinan S, et al. Delayed gastric emptying in Parkinson’s disease. Mov Disord. 2014;29:23‐32. https://www.ncbi.nlm.nih.gov/pubmed/24151126

Müller T. Safinamide: an add-on treatment for managing Parkinson’s disease. Clin Pharmacol. 2018;10:31-41. https://www.ncbi.nlm.nih.gov/pubmed/29670409

Nyholm D, et al. Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson’s disease patients. AAPS J. 2013;15:316-323. https://www.ncbi.nlm.nih.gov/pubmed/23229334

Olanow CW, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13:141-149. https://www.ncbi.nlm.nih.gov/pubmed/24361112

Pahwa R, et al. Amantadine extended release for levodopa-induced dyskinesia in Parkinson’s disease (EASED Study). Mov Disord. 2015;30:788-795. https://www.ncbi.nlm.nih.gov/pubmed/25650051

Pedersen SW, et al. Practical Guidance on How to Handle Levodopa/Carbidopa Intestinal Gel Therapy of Advanced PD in a Movement Disorder Clinic. Open Neurol J. 2012;6:37-50. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3406266/

Politis M, et al. Parkinson’s disease symptoms: the patient’s perspective. Mov Disord. 2010;25:1646-1651. https://www.ncbi.nlm.nih.gov/pubmed/20629164

Societies and Associations

Resource

Address

American Academy of Neurology

https://www.aan.com

American Parkinson Disease Association

https://www.apdaparkinson.org/

Michael J. Fox Foundation

https://www.michaeljfox.org/

Parkinson Alliance

https://www.parkinsonalliance.org/

Parkinson’s Foundation

https://www.parkinson.org/

Parkinsons

Copyright © 2019 | Thrive Parkinsons | All Rights Reserved | Website by Divigner

Patient Toolkit

The THRIVE Patient Toolkit is a resource center for patients who received diagnosis of or who are interested in learning about Parkinson’s disease. Choose from the options below to learn more.

Clinical Toolkit

The THRIVE Clinical Toolkit is an online tool that aims to provide clinicians up-to-date information on the presentation, prognosis, pathophysiology, and treatment strategies for Parkinson’s disease. Click on one of the options below to learn more about PD.

This activity is supported by an independent medical education grant from AbbVie.

Copyright © 2019 | Diabetic Retinopathy | All Rights Reserved | Website by Divigner